Morningstar

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Provided by Dow Jones

By Grace Yoon 




  Johnson & Johnson said it came to a strategic agreement with Sail Biomedicines to advance its immune-mediated disease program and broader technology platform. 



  The collaboration comes with the incentive of expanding the application of Sail's in vivo CAR-T platform across additional therapeutic targets over time. 



  Johnson & Johnson will also make an equity investment in Sail, and was granted an exclusive option to acquire Sail for $2.58 billion. 



  John Reed, Johnson & Johnson's executive vice president of innovative medicine research and development, said by working with Sail the company would aim to accelerate the development of innovative therapies. 



  Under the agreement, Johnson & Johnson would make total initial payments of $785 million, including a $465 million equity investment, and additional contingent payments of $140 million if certain development milestones are achieved. 



  Johnson & Johnson also completed its acquisition of Firefly Bio, a biotechnology company, for $1 billion. The Firelink DAC platform for KRAS-driven tumors bolsters Johnson & Johnson's oncology pipeline, Johnson & Johnson said. 





  Write to Grace Yoon at grace.yoon@wsj.com 





  (END) Dow Jones Newswires



  July 29, 2026 18:20 ET (22:20 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for October
 
Plus, lessons from September’s stock market activity. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
 
With a 3.3% dividend yield and earnings growth expected to exceed management’s outlook, this 4-star stock stands out in a struggling sector. 
 
 
Andrew Bischof, CFA, CPA 
 
 
 
The Thrilling 37
 
Just a few strict screens can narrow the field to an elite group of funds. 
 
 
Russel Kinnel 
 
 
 
3 Stocks to Invest In With More Room to Run
 
These stocks are up significantly in 2026, yet still look undervalued today. 
 
 
Susan Dziubinski 
 
 
 
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
 
Ask the Analyst columnist Amy Arnott answers a grab bag of reader questions about bond ETFs, TIPS, retirement planning, and more. 
 
 
Amy C. Arnott, CFA and Ivanna Hampton 
 
 
 
 

			Sponsor Center